Kisspeptin-10 Reference

Plain English

What it is

Kisspeptin-10 is a research peptide, not an approved medicine. It is a small piece of a natural body hormone called kisspeptin, which acts like an on switch in the brain for the signals that control the sex hormones.

What people use it for

In peptide communities people talk about it to nudge the brain signal (LH) that tells the body to make testosterone, and for fertility, libido, and restarting the body's own hormone production after it has been quiet.

What the science shows

Human studies show that a single dose can cause a short, quick rise in LH, and a steady drip can raise testosterone for a while. But most published fertility research relied on a different, longer-lasting piece of the hormone (kisspeptin-54), not kisspeptin-10, and the two do not behave the same. There is no proof it reliably improves testosterone, fertility, or libido.

The catch

It is not FDA-approved and stays in research only, and its long-term safety is not known. Kisspeptin-10 clears from the blood within minutes, so the idea of it acting as a long-lasting libido or fertility peptide is not backed by the studies. The vials sold to the community are not the same peptide used in the trials.

Reference summary

Kisspeptin-10 is the C-terminal decapeptide of the parent kisspeptin-54 (KP-54); both share the C-terminal RF-amide motif that activates KISS1R, but they differ pharmacokinetically. KP-10 plasma half-life in humans is about 4 minutes (Jayasena et al., 3.8 +/- 0.3 min in men, 4.1 +/- 0.4 min in women), while KP-54 plasma half-life is about 28 minutes (Dhillo 2005 reported 27.6 +/- 1.1 min IV). Most of the published human trial program (Imperial College London: Dhillo, Jayasena, Abbara) uses KP-54 for sustained signaling; the IVF-trigger paper is Jayasena 2014 J Clin Invest (PMID 25036713, 53 women, 12 clinical pregnancies with subsequent live births reported), and Abbara 2015 J Clin Endocrinol Metab (PMID 26192876, 60 women) extended the work in women at high risk of ovarian hyperstimulation syndrome. KP-10 work is dominated by single-pulse acute LH-response probes (peak ~20 to 40 minutes after IV bolus, with return toward baseline typically within ~1 hour at the doses studied). These findings do not validate self-directed fertility, testosterone, libido, or hormone-restart use.

Regulatory and posture

Categories

Hormonal, Reproductive

Aliases

Kp-10, KP10, Metastin fragment, KISS1-derived decapeptide

Evidence posture

human - KP-54 (not KP-10) is the peptide used in the IVF-trigger and amenorrhea-probe trials that the community often cites. The two fragments are pharmacokinetically distinct; equivalence by dose is not established. Research-vial KP-10 sold to the community is not the trial peptide. No FDA-approved product. No validated long-term outcome program.

Regulatory status

No FDA-approved kisspeptin-10 drug label. KISS1 was originally identified in 1996 as a melanoma metastasis suppressor gene at Penn State College of Medicine in Hershey, Pennsylvania (the name kisspeptin references Hershey's Kisses). The reproductive role was established in 2003 when de Roux (Proc Natl Acad Sci USA, PMID 12944565) and Seminara (N Engl J Med, PMID 14573733) independently reported that loss-of-function variants in KISS1R (formerly GPR54) cause normosmic hypogonadotropic hypogonadism, identifying kisspeptin signaling as the upstream activator of GnRH neurons. Kisspeptin-10 remains investigational worldwide; no human kisspeptin product is FDA-approved for any indication.

Content review status

research reference

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.